Ionis Pharmaceuticals (IONS) Misses Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- US stock futures muted as oil stays above $100 ahead of earnings
- Oil prices fluctuate on Trump's Russian diesel comments, attacks on Saudi
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- US consumer sentiment near record low as frustration over economy mounts
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
Ionis reports second quarter financial results and recent business achievements
August 9, 2022 7:00 AM EDTReported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22
Tofersen NDA under priority review, PDUFA January 25, 2023
Completed enrollment in pelacarsen Lp(a) HORIZON and olezarsen BALANCE Phase 3 studies
On track to achieve 2022 financial guidance
Webcast today, August 9, 2022, at 11:30 a.m. Eastern Time
CARLSBAD, Calif., Aug. 9, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the second quarter of 2022Â and recent business achievements.
... More


